These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17598142)

  • 1. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity.
    Auclair JR; Green KM; Shandilya S; Evans JE; Somasundaran M; Schiffer CA
    Proteins; 2007 Nov; 69(2):270-84. PubMed ID: 17598142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
    Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
    Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions.
    Paul I; Cui J; Maynard EL
    Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18475-80. PubMed ID: 17132731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The viral infectivity factor (Vif) of HIV-1 unveiled.
    Rose KM; Marin M; Kozak SL; Kabat D
    Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Sheehy AM; Gaddis NC; Malim MH
    Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors.
    Hultquist JF; Binka M; LaRue RS; Simon V; Harris RS
    J Virol; 2012 Mar; 86(5):2874-7. PubMed ID: 22205746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
    Goncalves J; Santa-Marta M
    Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Marin M; Rose KM; Kozak SL; Kabat D
    Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent insights into HIV-1 Vif.
    Navarro F; Landau NR
    Curr Opin Immunol; 2004 Aug; 16(4):477-82. PubMed ID: 15245742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
    Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
    Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Enhanced protein production of Vif and APOBEC3G by HIV-1 Vpr].
    Li L; Liang D; Li JY; Zhao YQ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Feb; 22(1):39-41. PubMed ID: 18414697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular structure and biochemical properties of the HCCH-Zn2+ site in HIV-1 Vif.
    Giri K; Scott RA; Maynard EL
    Biochemistry; 2009 Aug; 48(33):7969-78. PubMed ID: 19588889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
    Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
    J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
    Schröfelbauer B; Chen D; Landau NR
    Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3927-32. PubMed ID: 14978281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biophysical characterization of recombinant HIV-1 subtype C virus infectivity factor.
    Gallerano D; Devanaboyina SC; Swoboda I; Linhart B; Mittermann I; Keller W; Valenta R
    Amino Acids; 2011 Mar; 40(3):981-9. PubMed ID: 20809132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.